Anaptys Announces Participation in December Investor Conferences
Globe Newswire (Tue, 25-Nov 4:15 PM ET)
AnaptysBio’s $100 Million Stock Repurchase Plan Underscores Strong Cash Position and Strategic Shift
Market Chameleon (Fri, 21-Nov 3:56 AM ET)
Anaptys Announces $100 Million Stock Repurchase Plan
Globe Newswire (Fri, 21-Nov 4:00 AM ET)
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
Globe Newswire (Fri, 21-Nov 3:50 AM ET)
Globe Newswire (Mon, 10-Nov 9:00 AM ET)
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
Globe Newswire (Tue, 4-Nov 4:15 PM ET)
Anaptys Announces Participation in November Investor Conferences
Globe Newswire (Tue, 4-Nov 4:15 PM ET)
Globe Newswire (Wed, 29-Oct 9:15 AM ET)
Globe Newswire (Mon, 13-Oct 9:15 AM ET)
Anaptys Sets Sights on Split: Biopharma and Royalty Businesses to Operate Independently by 2026
Market Chameleon (Tue, 30-Sep 6:31 AM ET)
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Anaptysbio trades on the NASDAQ stock market under the symbol ANAB.
As of December 10, 2025, ANAB stock price climbed to $44.57 with 88,983 million shares trading.
ANAB has a beta of 0.46, meaning it tends to be less sensitive to market movements. ANAB has a correlation of 0.01 to the broad based SPY ETF.
ANAB has a market cap of $1.25 billion. This is considered a Small Cap stock.
Last quarter Anaptysbio reported $76 million in Revenue and $.52 earnings per share. This beat revenue expectation by $51 million and exceeded earnings estimates by $1.69.
In the last 3 years, ANAB traded as high as $46.56 and as low as $12.21.
The top ETF exchange traded funds that ANAB belongs to (by Net Assets): VTI, IWM, XBI, IBB, VXF.
ANAB has outperformed the market in the last year with a price return of +94.8% while the SPY ETF gained +14.3%. ANAB has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +101.4% and +7.4%, respectively, while the SPY returned +5.4% and +1.3%, respectively.
ANAB support price is $41.87 and resistance is $45.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANAB shares will trade within this expected range on the day.